<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="54133"><TitleDisplay>Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer</TitleDisplay><TitleOfficial>Evaluation of Novel Therapeutic Agents Against Breast Cancer: An Innovative Randomized Phase II Trial Design</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CALGB-49806</Identifier><Identifier type="NCT">NCT00004893</Identifier><Identifier type="Secondary Organisational">CLB-49806</Identifier><Identifier type="Secondary Organisational">U10CA031946</Identifier><Identifier type="Other">CDR0000067570</Identifier></Identifiers><Indications><Indication id="3657">Metastatic breast cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>edodekin alfa</Name><Drug id="6934">edodekin alfa</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6934">edodekin alfa</Drug><IndicationsPioneer><Indication id="3657">Metastatic breast cancer</Indication></IndicationsPioneer><Companies><Company><Company id="1122738">Alliance Foundation Trials LLC</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6934" type="Drug"><TargetEntity id="164387" type="siDrug">Edodekin alfa</TargetEntity></SourceEntity><SourceEntity id="1122738" type="Company"><TargetEntity id="5050902506" type="organizationId">Alliance Foundation Trials LLC</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"></TargetEntity><TargetEntity id="589" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>49</NumberOfSites><CompaniesSponsor><Company id="1122738">Alliance Foundation Trials LLC</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="51207">Interleukin 12 ligand</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2638">Antiparasitic</Class><Class id="393">Immunostimulant</Class><Class id="62253">Anticancer hormone</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>5</PatientCountEnrollment><DateStart>1999-12-31T00:00:00Z</DateStart><DateEnd type="actual">2002-02-28T00:00:00Z</DateEnd><DateChangeLast>2016-07-29T11:51:35Z</DateChangeLast><DateAdded>2009-05-06T11:38:59Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Michigan Cancer Center</Affiliation><Name>Daniel F. Hayes, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics:&lt;ul&gt;&lt;li&gt;Histologically confirmed metastatic or recurrent breast cancer (not confined to breast)&lt;/li&gt;&lt;li&gt;One prior induction chemotherapy regimen for recurrent or metastatic disease (4 weeks of treatment for four to six courses) resulting in stable disease, partial response, or complete response&lt;/li&gt;&lt;li&gt;Pleural or peritoneal effusion palliated by induction chemotherapy allowed&lt;/li&gt;&lt;li&gt;No uncontrolled brain metastases&lt;/li&gt;&lt;li&gt;Previously treated brain metastases allowed if:&lt;ul&gt;&lt;li&gt;No evidence of progression for at least 3 months following radiotherapy and/or surgical treatment&lt;/li&gt;&lt;li&gt;At least 30 days since dexamethasone or other corticosteroids&lt;/li&gt;&lt;li&gt;Other metastatic site exists&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No bone marrow or brain as only sites of metastases&lt;/li&gt;&lt;li&gt;No meningeal disease&lt;/li&gt;&lt;li&gt;Hormone receptor status: Estrogen receptor status known&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient characteristics:&lt;ul&gt;&lt;li&gt;Age: 18 years and over&lt;/li&gt;&lt;li&gt;Performance status: ECOG 0 or 1&lt;/li&gt;&lt;li&gt;Menopausal status: not specified&lt;/li&gt;&lt;li&gt;Life expectancy: not specified&lt;/li&gt;&lt;li&gt;Hematopoietic:&lt;ul&gt;&lt;li&gt;WBC at least 3000/mm3&lt;/li&gt;&lt;li&gt;Absolute neutrophil count at least 1500/mm3&lt;/li&gt;&lt;li&gt;Hemoglobin at least 9 g/dl (transfusion or epoetin alfa allowed)&lt;/li&gt;&lt;li&gt;Platelet count at least 100,000/mm3&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Hepatic:&lt;ul&gt;&lt;li&gt;SGOT/SGPT no &gt; 1.5 times upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Albumin at least 3.0 g/dl&lt;/li&gt;&lt;li&gt;Bilirubin no &gt; 1.5 times ULN&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Renal:&lt;ul&gt;&lt;li&gt;Creatinine no &gt; 1.5 times ULN&lt;/li&gt;&lt;li&gt;Creatinine clearance at least 60 ml/min&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;No other active malignancy except nonmelanoma skin cancer&lt;/li&gt;&lt;li&gt;Not pregnant or nursing&lt;/li&gt;&lt;li&gt;Fertile patients must use effective contraception&lt;/li&gt;&lt;li&gt;No inflammatory bowel disease or active gastric ulcer&lt;/li&gt;&lt;li&gt;No prior autoimmune disease or immunodeficiency syndrome&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior concurrent therapy:&lt;ul&gt;&lt;li&gt;Biological therapy:&lt;ul&gt;&lt;li&gt;See chemotherapy&lt;/li&gt;&lt;li&gt;No concurrent interleukin-11&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Chemotherapy:&lt;ul&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;li&gt;No concurrent chemotherapy&lt;/li&gt;&lt;li&gt;Prior chemotherapy with bone marrow progenitor support (bone marrow transplant and/or peripheral blood stem cell support) allowed in adjuvant setting only (not for metastases)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Endocrine therapy:&lt;ul&gt;&lt;li&gt;Prior hormone therapy for breast cancer allowed&lt;/li&gt;&lt;li&gt;No concurrent hormones allowed except for non-cancer or cancer treatment related conditions (eg, insulin for diabetes)&lt;/li&gt;&lt;li&gt;No concurrent dexamethasone or other steroidal antiemetics&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Radiotherapy:&lt;ul&gt;&lt;li&gt;Prior radiotherapy allowed&lt;/li&gt;&lt;li&gt;No concurrent radiotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Surgery: not specified&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;Prior bisphosphonate therapy allowed if started at least 3 months before study&lt;/li&gt;&lt;li&gt;No initiation of bisphosphonate therapy during study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Disease progression</Description><Timeframe>At 6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Time to progression</Description><Timeframe>Up to one year</Timeframe></Measure><Measure><Description>Overall survival</Description><Timeframe>Up to one year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized phase II trial was  to study the effectiveness of &lt;ulink linkType="Drug" linkID="6934"&gt;interleukin-12&lt;/ulink&gt; in treating patients who have metastatic or recurrent breast cancer.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The objectives of the study were to: &lt;br/&gt;Determine the activity of &lt;ulink linkType="Drug" linkID="6934"&gt;interleukin-12&lt;/ulink&gt; as defined by the percentage of patients who have not progressed after 6 months of therapy.
&lt;br/&gt;Compare percentage of patients who have not progressed after 6 months with or without treatment regimen.
&lt;br/&gt;Determine time to progression and overall survival in this patient population after this treatment.
&lt;/para&gt;&lt;para&gt;This was a randomized study.  Patients would be  stratified according to disease free interval from primary diagnosis to first metastases (&amp;lt; 3 years versus 3 years and longer), estrogen receptor status (positive versus negative), and disease status (complete response, partial response, detectable disease, or stable disease).  Patients would be   randomized to one of two treatment arms.
&lt;/para&gt;&lt;para&gt;Arm I:  patients would   begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose.  Patients would receive &lt;ulink linkType="Drug" linkID="6934"&gt;interleukin-12&lt;/ulink&gt; sc biw.  Treatment would continue in the absence of disease progression or unacceptable toxicity.  Patients would be  followed at least every 3 months for one year.  If no progression after one year, may be followed as needed for new signs or symptoms and survival for five years.
&lt;/para&gt;&lt;para&gt;Arm II:  patients would be  observed for 6 months.  If disease progresses during first 6 months, patients may receive &lt;ulink linkType="Drug" linkID="6934"&gt;interleukin-12&lt;/ulink&gt; as in arm I.  Patients without disease progression within first 6 months may also then receive &lt;ulink linkType="Drug" linkID="6934"&gt;interleukin-12&lt;/ulink&gt; as in arm I.  Treatment would continue in the absence of disease progression or unacceptable toxicity.  Patients would be  followed for toxicity only until &lt;ulink linkType="Drug" linkID="6934"&gt;interleukin-12&lt;/ulink&gt; was discontinued.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This trial was terminated because of poor accrual.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Veterans Affairs Medical Center - Birmingham</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3>35233</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>UCSF Cancer Center and Cancer Research Institute</Name><Address1>San Francisco</Address1><Address2>California</Address2><Address3>94115-0128</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of California San Diego Cancer Center</Name><Address1>La Jolla</Address1><Address2>California</Address2><Address3>92093-0658</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - San Francisco</Name><Address1>San Francisco</Address1><Address2>California</Address2><Address3>94121</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CCOP - Christiana Care Health Services</Name><Address1>Wilmington</Address1><Address2>Delaware</Address2><Address3>19899</Address3><CountrySubDivision code="DE">Delaware</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Lombardi Cancer Center, Georgetown University</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><Address3>20007</Address3><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Walter Reed Army Medical Center</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><Address3>20307-5000</Address3><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CCOP - Mount Sinai Medical Center</Name><Address1>Miami Beach</Address1><Address2>Florida</Address2><Address3>33140</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Chicago Cancer Research Center</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3>60637</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Illinois at Chicago Health Sciences Center</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3>60612</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - Chicago (Westside Hospital)</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3>60612</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Iowa Hospitals and Clinics</Name><Address1>Iowa City</Address1><Address2>Iowa</Address2><Address3>52242</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - Togus</Name><Address1>Togus</Address1><Address2>Maine</Address2><Address3>04330</Address3><CountrySubDivision code="ME">Maine</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Marlene &amp; Stewart Greenebaum Cancer Center, University of Maryland</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21201</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Dana-Farber Cancer Institute</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Massachusetts Memorial Medical Center</Name><Address1>Worcester</Address1><Address2>Massachusetts</Address2><Address3>01655</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Minnesota Cancer Center</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55455</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - Minneapolis</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55417</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Barnes-Jewish Hospital</Name><Address1>Saint Louis</Address1><Address2>Missouri</Address2><Address3>63110</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Ellis Fischel Cancer Center - Columbia</Name><Address1>Columbia</Address1><Address2>Missouri</Address2><Address3>65203</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - Columbia (Truman Memorial)</Name><Address1>Columbia</Address1><Address2>Missouri</Address2><Address3>65201</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Nebraska Medical Center</Name><Address1>Omaha</Address1><Address2>Nebraska</Address2><Address3>68198-3330</Address3><CountrySubDivision code="NE">Nebraska</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CCOP - Southern Nevada Cancer Research Foundation</Name><Address1>Las Vegas</Address1><Address2>Nevada</Address2><Address3>89106</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Norris Cotton Cancer Center</Name><Address1>Lebanon</Address1><Address2>New Hampshire</Address2><Address3>03756</Address3><CountrySubDivision code="NH">New Hampshire</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CCOP - North Shore University Hospital</Name><Address1>Manhasset</Address1><Address2>New York</Address2><Address3>11030</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.</Name><Address1>Syracuse</Address1><Address2>New York</Address2><Address3>13217</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Memorial Sloan-Kettering Cancer Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10021</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mount Sinai Medical Center, NY</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10029</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>New York Presbyterian Hospital - Cornell Campus</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10021</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>North Shore University Hospital</Name><Address1>Manhasset</Address1><Address2>New York</Address2><Address3>11030</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Roswell Park Cancer Institute</Name><Address1>Buffalo</Address1><Address2>New York</Address2><Address3>14263-0001</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>State University of New York - Upstate Medical University</Name><Address1>Syracuse</Address1><Address2>New York</Address2><Address3>13210</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - Buffalo</Name><Address1>Buffalo</Address1><Address2>New York</Address2><Address3>14215</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - Syracuse</Name><Address1>Syracuse</Address1><Address2>New York</Address2><Address3>13210</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Duke Comprehensive Cancer Center</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><Address3>27710</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Lineberger Comprehensive Cancer Center, UNC</Name><Address1>Chapel Hill</Address1><Address2>North Carolina</Address2><Address3>27599-7295</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - Durham</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><Address3>27705</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Arthur G. James Cancer Hospital - Ohio State University</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43210</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Rhode Island Hospital</Name><Address1>Providence</Address1><Address2>Rhode Island</Address2><Address3>02903</Address3><CountrySubDivision code="RI">Rhode Island</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Medical University of South Carolina</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><Address3>29425-0721</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Tennessee, Memphis Cancer Center</Name><Address1>Memphis</Address1><Address2>Tennessee</Address2><Address3>38103</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - Memphis</Name><Address1>Memphis</Address1><Address2>Tennessee</Address2><Address3>38104</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CCOP - Southwestern Vermont Regional Cancer Center</Name><Address1>Bennington</Address1><Address2>Vermont</Address2><Address3>05201</Address3><CountrySubDivision code="VT">Vermont</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Vermont Cancer Center</Name><Address1>Burlington</Address1><Address2>Vermont</Address2><Address3>05401-3498</Address3><CountrySubDivision code="VT">Vermont</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - White River Junction</Name><Address1>White River Junction</Address1><Address2>Vermont</Address2><Address3>05009</Address3><CountrySubDivision code="VT">Vermont</CountrySubDivision><Contacts></Contacts></Site><Site><Name>MBCCOP - Massey Cancer Center</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><Address3>23298-0037</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Veterans Affairs Medical Center - Richmond</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><Address3>23249</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CCOP - Southeast Cancer Control Consortium</Name><Address1>Winston-Salem</Address1><Address2>North Carolina</Address2><Address3>27104-4241</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Comprehensive Cancer Center of Wake Forest University Baptist Medical Center</Name><Address1>Winston-Salem</Address1><Address2>North Carolina</Address2><Address3>27157-1082</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3954">Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3966">Subjects with Relapsed/Recurrent Breast cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00004893</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><OtherEndpoints><OtherEndpoint disease="Breast tumor" id="8712"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Breast tumor" id="8744"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8745">Assessment of Time to Tumor Progression (TTP)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Breast tumor" id="9043"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="9049">Assessment of Antitumor Activity</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4840"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4832">Subjects with brain/leptomeningeal metastases</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4870"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4878"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4879">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Breast tumor" id="4880">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4893"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4894">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Breast tumor" id="4895">Subjects with history of anti-cancer hormonal therapy</SubCriterion><SubCriterion disease="Breast tumor" id="4904">Subjects with history of anti-cancer radiotherapy</SubCriterion><SubCriterion disease="Breast tumor" id="22394">Subjects with history of anti-cancer biological therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4906"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4903">Subjects with history of bisphosphonates therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4923"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6260"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6272"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6294"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6328"><Criterion>Subjects with History of/Scheduled for Anti-neoplastic Therapy</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6377"><Criterion>Subjects with history of/planned radiotherapy</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6393"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Breast tumor" id="26375"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6247">Subjects with Brain/Leptomeningeal metastases</SubCriterion><SubCriterion disease="Breast tumor" id="6248">Subjects with Bone metastases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26805"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="20289">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2002-02-28T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-05-06T11:38:59Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>